Back

Hot Pursuit

Emcure Pharmaceuticals advanced 1.25% to Rs 1,271.85 after U.S. Food and Drug Administration (USFDA) conducted pre-approval inspection (PAI) at its manufacturing facility (Oncology) located at G.I.D.C, Sanand, Ahmedabad, Gujarat.

Emcure Pharma gains after Sanand facility gets zero observations from USFDA

10-Jul-2025, 09:50
The inspection conducted from 30 June 2025 to 08 July 2025 and concluded without issuance of Form 483, indicating zero observations.

Pune-based Emcure Pharmaceuticals is a leading Indian pharma company engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products.

The company's consolidated net profit jumped 64.1% to Rs 188.96 crore on 19.5% increase in net sales to Rs 2,116.25 crore in Q4 FY25 over Q4 FY24.